

PRODUCT INFORMATION



(S)-(+)-Clopidogrel-d₃ (sulfate)

Item No. 10010673

Formal Name: methyl-d₃ (S)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate sulfate

MF: C₁₆H₁₃ClD₃NO₂S • H₂SO₄

FW: 422.9

Chemical Purity: ≥90% ((S)-(+)-Clopidogrel (sulfate))


Deuterium

Incorporation: ≥99% deuterated forms (d₁-d₃); ≤1% d₀

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

(S)-(+)-Clopidogrel-d₃ is intended for use as an internal standard for the quantification of (S)-(+)-clopidogrel (Item No. 21002) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

(S)-(+)-Clopidogrel-d₃ (sulfate) is supplied as a crystalline solid. A stock solution may be made by dissolving the (S)-(+)-clopidogrel-d₃ (sulfate) in the solvent of choice. (S)-(+)-Clopidogrel-d₃ (sulfate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of (S)-(+)-clopidogrel-d₃ (sulfate) in ethanol is approximately 3 mg/ml and approximately 10 mg/ml in DMSO and DMF.

Description

(S)-(+)-Clopidogrel is a prodrug form of the active metabolite of clopidogrel, which is a purinergic P2Y₁₂ receptor antagonist.¹ It inhibits aggregation of rat platelets induced by ADP, collagen, or thrombin *ex vivo* (ID₅₀s = 4, 4.8, and 2.9 mg/kg, respectively). (S)-(+)-Clopidogrel increases tail bleeding time in rats in a dose-dependent manner. Formulations containing (S)-(+)-clopidogrel have been used in the treatment of acute coronary syndrome and peripheral artery disease and to reduce the reoccurrence of myocardial infarction and stroke.

Reference

1. Herbert, J., Frehel, D., Vallée, E., *et al.* Clopidogrel, a novel antiplatelet and antithrombotic agent. *Cardiovasc. Drug Rev.* **11**(2), 180-198 (1993).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/06/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM